Various staphylococci produce small, highly modified peptides that exert antibiotic activity mainly against grampositive bacteria. These lantibiotics, which have lanthionine as a characteristic component, are ribosomally synthesized as prepeptides and posttranslationally converted into the mature peptides. The structures and prepeptide sequences of the following lantibiotics from various staphylococcal strains have been determined (reviewed in reference 13): epidermin (1, 33) , gallidermin (18, 32) , and Pep5 (17, 19) . Additional lantibiotics are produced by a variety of microorganisms, such as lactococci, bacilli, and actinomycetes (reviewed in reference 16). The cationic lantibiotics interact with cytoplasmic membranes of bacteria and form transient, potentialdependent pores, thus causing efflux of ions and small molecules (21, 27) .
Epidermin, which is produced and secreted into the medium by Staphylococcus epidermidis Tu3298, can be purified by reversed-phase high-performance liquid chromatography (12) . The optimization of fermentative production leads to a large increase in the epidermin yield (14) . Epidermin consists of a polycyclic heterodet peptide possessing thioether amino acids, such as meso-lanthionine and 3-methyllanthionine, which form four intramolecular thioether bridges. Moreover, epidermin contains the a,1-unsaturated amino acid didehydroaminobutyric acid and S-[(Z)-2-aminovinyl]-D-cysteine (1) . Epidermin is ribosomally synthesized, as shown by the cloning and sequencing of the structural gene, epiA (33) . Recently, it was shown that epiA is the first gene of an operon comprising epiA4, epiB, epiC, and epiD. Two additional genes, epiQ and epiP, are transcribed in the opposite direction (31) . All genes are located on the 54-kb plasmid pTu32 of S. epidermidis Tu3298. The involvement of the gene products in epidermin biosynthesis was verified by complementation analysis of S. epidermidis mutants (3, 4) * Corresponding author.
and by heterologous gene expression in Staphylococcus camosus (31) .
Epidermin is synthesized as a 52-amino-acid prepeptide (N-terminal leader peptide with amino acids -30 to -1 and C-terminal segment with amino acids +1 to +22), which is posttranslationally modified and processed to the mature tetracyclic 22-amino-acid peptide antibiotic (33) . The proposed modifying reactions comprise dehydration of serine and threonine residues, sulfide bridge formation, and oxidative decarboxylation at the C terminus (very likely catalyzed by EpiB, EpiC, and EpiD). So far, lantibiotic synthesizing enzymes have not been purified, nor have experimental data been presented elucidating the roles of the enzymes in lantibiotic biosynthesis.
Here we report the cloning and overexpression of epiD in Eschenchia coli, the raising of anti-EpiD polyclonal antibodies, the purification of EpiD and a maltose-binding protein (MBP)-EpiD fusion protein, and the coenzyme flavin mononucleotide (FMN) dependence of the enzymes. Furthermore, we identify the genetic basis of the epiD mutation of S. epidermidis Tu3298/EMS11 and its effect on the FMN binding of MBP-EpiD. Based on the conclusion that EpiD is a flavoprotein, we propose a model for its function in epidermin biosynthesis.
MATERIALS AND METHODS
Bacterial strains and plasmids. The epiC and epiD genes from S. epidermidis Tu3298 (DSM 3095) were cloned in E. coli K38 (26) (24) . Cells were lysed by the addition of lysostaphin (8 ,ug/ml), and the DNA was isolated by CsCl centrifugation. E. coli supercoiled plasmid DNA was prepared by the modified alkaline lysis method (6) . E. coli was transformed by electroporation (10). Established protocols were followed for molecular biological techniques (28) . Enzymes for molecular cloning were obtained from Boehringer (Mannheim, Germany), BRL (Eggenstein, Germany), and Pharmacia LKB (Freiburg, Germany); assay conditions were as recommended by the suppliers.
DNA sequencing and amplification by the polymerase chain reaction (PCR). The malE-epiD and malE-epiD* fusions were sequenced by double-stranded DNA sequencing (9) by using the dideoxy procedure (29) Expression studies using the T7 RNA polymerase-promoter system. The T7 expression system described by Tabor and Richardson (34) was used. epiC and epiD were cloned into the T7 promoter-containing vector pT7-5. The resulting recombinant plasmids (Fig. 1) (2) . The vector pIH902 has an exact deletion at the malE signal sequence, which leads to a cytoplasmic location of the fusion protein. The fusion protein was expressed and purified as described by Riggs (25) . Plasmid pIH902-epiD was transformed into E. coli TB1; transformants were selected with ampicillin (100 ,ug/ml) and identified by using 5-bromo-4-chloro-3-indolyl-3-D-galactopyranoside and isopropyl-13-D-thiogalactopyranoside (IPTG) (80 ,ug/ml and 0.1 mM, respectively). White clones were picked and tested for expression of the MBP-EpiD fusion protein. A 1% inoculated culture grown to a density of 0.45 (A60) was then induced by the addition of 0.3 mM IPTG and cultivated for another 2 h. A 300-,ul sample of the cell culture was centrifuged, and the pellet was resuspended in 100 pI of Laemmli sample buffer (22) and boiled for 5 min; an aliquot was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western immunoblotting. E. coli TB1(pIH902) was used as a control.
For purification of the MBP-EpiD fusion protein, IPTGinduced cells were centrifuged, the pellet was resuspended in column buffer (10 mM phosphate, 0.5 M NaCl, 1 mM sodium azide, 10 mM 2-mercaptoethanol, 0.25% Tween 20) , and the cells were disrupted with glass beads (0.22-mm diameter). After two centrifugation steps (15 min at 6,000 x g and 60 min at 150,000 x g), the cell extract was applied to amylose resin equilibrated with column buffer. Unbound proteins were removed with 5 volumes of column buffer, and the resin was then washed with 5 volumes of column buffer lacking Tween to remove the detergent. Amylose-bound proteins were eluted with 10 mM maltose in column buffer lacking Tween and monitored byA280 andA450. The residual malE expression was largely repressed by the addition of glucose to the medium.
Immunization procedure. For primary immunization, New Zealand White rabbits were injected subcutaneously with 1 mg of MBP-EpiD fusion protein dissolved in 1.5 ml of phosphate-buffered saline and emulsified in Freud's complete adjuvant. After 4 weeks, the rabbits were given intramuscular booster injections of 100 pug of protein in phosphate-buffered saline; the antisera were collected after three booster injections at 1-week intervals.
Factor Xa cleavage. Purified MBP-EpiD fusion protein was dialyzed against factor Xa buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 mM CaCl2), and the protein concentration was adjusted to 1 mg/ml. After factor Xa (1 U of factor Xa per 100 ,ug of fusion protein) was added, the mix was incubated for several hours at 25°C. Cleavage was monitored by SDS-PAGE and Western blotting.
Purification of EpiD from E. coli. E. coli K38(pGP1-2, pT7-SepiD) was aerobically cultivated in 2.5 liters at 300C to an A600 of 0.45. For induction of T7 RNA polymerase, the temperature was shifted to 42°C for 30 min and cultivation was then continued at 37°C for 2 h. All subsequent steps were performed at 40C. Cultures were harvested by centrifugation. Four weight equivalents of glass beads and 2 volumes of 20 mM Tris-HCl (pH 8.0) buffer were added to the cell pellet. The cells were disrupted in a Corex test tube by vortexing for 2 min. Glass beads and unbroken cells were pelleted by centrifugation at 6,000 x g for 15 min. The supernatant was centrifuged at 150,000 x g for 1 h, and the pelleted membrane fraction was discarded. The cytosolic fraction was subjected to DEAE-Sepharose Fast Flow chromatography (20 ml of wet column resin) in a column equilibrated with 20 mM Tris-HCl (pH 8.0). Proteins were eluted with a linear gradient of 0 to 500 mM NaCl in 10 bed volumes of 20 mM Tris-HCl (pH 8.0) with a flow rate of 120 ml/h. Elution of EpiD was followed at A280 and A450 ( Flavin identification. The coenzyme could be directly removed from purified EpiD by heat denaturation (8 min, 100°C). The MBP-EpiD fusion protein was precipitated by heat denaturation (8 min, 100°C), and the coenzyme was removed by treatment with cold 5% trichloroacetic acid and subsequent neutralization as described previously (23) . The coenzyme was analyzed by thin-layer chromatography on cellulose-aluminum sheets with the following three solvents (20) : (i) n-butyl alcohol-acetic acid-water (4:3:3), (ii) 5% Na2HPO4 in water, and (iii) tert-butyl alcohol-water (6:4 
RESULTS
Construction and purification of MBP-EpiD fusion proteins. The epidermin biosynthesis genes epiA, epiB, epiC, and epiD are organized as an operon (31) . A portion of the operon containing epiD is shown in Fig. 1 . According to the DNA sequence, epiD encodes a 181-amino-acid protein. To obtain more information on its function and biochemical properties, we first tried to express epiD in E. coli by using the MBP fusion system. By synthesizing specific primers, epiD was amplified by the PCR in such a way that the amplified DNA fragment started exactly with the ATG start codon and ended a few base pairs after the TAA stop codon. This fragment was inserted at the single StuI site of the pIH902 polylinker. In the resulting malE-epiD fusion, the epiD start codon immediately followed the factor Xa cleav- We took advantage of the destruction of the pIH902 StuI site (AGG/CCT) in this construct by incubating the ligation products with StuI before transformation in E. coli TB1; thus, the percentage of transformants with the religated vector was markedly reduced from 99.8% to less than 40%. The fusion protein MBP-EpiD was expressed by 30% of the transformants. The correct orientation and sequence of epiD in the malE-epiD fusion were determined by DNA sequencing with the malE, IH-rev, epiD-1, and epiD-2 primers.
Approximately 90% of the MBP-EpiD fusion protein was found in the soluble protein fraction of E. coli TBl(pIH902-epiD) cell extracts; there was no evidence that inclusion bodies were formed. The purification and location of the MBP-EpiD fusion protein were followed by SDS-PAGE and protein staining (Fig. 2A, lanes 1) . Near the expected size of the fusion protein (65 kDa), a 67-kDa protein was detectable only in cell extracts of IPTG-induced cells. Since this protein reacted with specific anti-MBP antibodies (Fig. 2B) Characterization of epiD* and its gene product. S. epidermidis Tu3298/EMS11 carries a mutation within epiD (4), designated epiD*, which was amplified by the PCR with purified pTu32 from the mutant as a template. This DNA fragment was inserted in the StuIl site of the pIH902 polylinker by the procedure described above for the malE-epiD fusion. Plasmids were isolated from four E. coli TB1 (pIH902-epiD*) clones, and the entire epiD* region was sequenced. The epiD* start codon immediately followed the factor Xa cleavage sequence, and all four isolated plasmids had a point mutation in codon 93, substituting the wild-type GEjT (Gly) with GAT (Asp) in epiD*. This G-to-A transition concurs with ethyl methanesulfonate as the mutagenizing agent (4) .
Production of MBP-EpiD* was followed by SDS-PAGE ( Fig. 2A, lanes 2 ) and Western blotting (Fig. 2B, lanes 2) . Most of MBP-EpiD* was found in the pellet fraction; the soluble protein fraction contained only 5 to 10% of the entire amount. This is in contrast to MBP-EpiD, most of which was found in the soluble protein fraction (compare lanes El and E2 of Fig. 2A) . It is very likely that inclusion bodies containing the MBP-EpiD* fusion were formed in E. coli. After amylose affinity chromatography, various immune reactive degradation products could be seen ( Fig. 2A and B , lanes F2); these results may indicate that MBP-EpiD* is more sensitive than the wild-type fusion protein to proteolytic degradation.
However, the most striking difference was that MBPEpiD* was not yellow and did not exhibit the characteristic absorption maxima of MBP-EpiD (see above and spectra 2 and 3 of Fig. 6B ) when similar concentrations of fusion proteins were used. For this comparison, it was necessary to dilute MBP-EpiD because of the small amount of soluble MBP-EpiD*. The pellet fraction was not yellow either. MBP-EpiD* was unable to bind FMN. Since MBP-EpiD* differed from MBP-EpiD only by the substitution of Gly-93 by Asp, Gly-93 may be important for FMN binding.
Expression of epiD in E. coli with the T7 promoter-polymerase system. It was previously demonstrated that the 3.1-kb HindIII-PvuII fragment of pTu32 complements both epiC and epiD mutants of S. epidermidis Tu3298, whereas the 1.7-kb EcoRI-BamHI fragment (Fig. 1) only complements the epiD mutant (4) . For gene expression studies, the 3.1-kb fragment containing epiC and epiD in the same orientation and epiQ and a portion of epiP in the opposite orientation was inserted by blunt-end ligation into the SmaI site of the T7 promoter-polymerase vector pT7-5 (pT7-5epiCD); the smaller fragment, in which most of epiC and epiP is deleted, was cloned in pT7-5 by EcoRI-BamHI ligation (pT7-SepiD). The correct orientation of the fragments (T7 promoter in front of epiCD) was checked by restriction analysis.
The E. coli-specific RNA polymerase was inhibited by rifampin, and the T7 promoter-controlled genes were preferentially expressed after heat induction. Expressed proteins were labeled with [35S]methionine, separated by SDS- PAGE, and visualized by autoradiography (Fig. 3) . In the presence of plasmid pT7-5epiCD, a major protein band at 44 kDa and two very narrow protein bands at 18 and 17 kDa were visible. The 44-kDa protein very likely represents EpiC. First, the molecular weight is similar to the expected value of 48,000; second, in the absence of epiC, this protein band and two other smaller ones (very likely degradation products) are absent (Fig. 3, lane 3) . Since the theoretical molecular mass of EpiD is 20.8 kDa, we assume that the 17-and 18-kDa proteins very likely represent EpiD. Potential explanations for the two migrating forms of EpiD are discussed below.
Comparison of epiD expression in E. coli with that in S. epidermidis Tu3298. Whole-cell lysates of uninduced and induced E. coli clones and cell extracts of S. epidermidis Tu3298 were analyzed by SDS-PAGE, and EpiD was detected by Western blotting with anti-MBP-EpiD antiserum (Fig. 4) . Based on densitometric comparison of the signal intensities of lane A3 [crude extract of E. coli(pGP1-2, pT7-5epiD)] with those of lane C (crude extract of S. epidermidis Tu3298), the concentration of EpiD was approximately 50-fold higher in the induced E. coli clones than in S. epidermidis Tu3298.
EpiD was poorly cleaved from MBP by factor Xa; less than 3% of the fusion protein was cleaved in 20 h (data not shown). Therefore, this method was not used to obtain purified EpiD. The separated EpiD reacted with anti-MBPEpiD antiserum (Fig. 4, lane B2) , as did the separated MBP.
Purification of EpiD from E. coli(pGP1-2, pT7-SepiD). EpiD was isolated from the soluble protein fraction of E. coli(pGP1-2, pT7-SepiD). It was purified to homogeneity in three chromatographic steps on DEAE-Sepharose Fast Flow, Mono-Q, and Phenylsuperose columns. In both anionexchange chromatographies, EpiD eluted at 300 mM NaCl; with Phenylsuperose chromatography, EpiD eluted at 0 M ammonium sulfate. From a 2.5-liter culture, 39.5 mg of soluble protein was obtained after cell disruption and ultracentrifugation. After Phenylsuperose chromatography, 0.1 mg of purified EpiD was recovered. Since approximately 75% of EpiD was lost in the course of purification, EpiD composes approximately 1% of the total soluble proteins. The various purification steps were followed by SDS-PAGE (Fig. 5A ) and immunoblotting with anti-MBP-EpiD antiserum (Fig. SB) . Here, too, purified EpiD migrated as a double band. All column chromatographic steps were monitored at A280 andA450. The EpiD content in the various fractions was always directly proportional to A450 (data not shown). Characterization of purified EpiD. The first 18 N-terminal amino acids of purified EpiD were determined by Edman degradation. The amino acid sequence correlated exactly with the postulated amino acids (Met-Tyr-Gly-Lys...) deduced from the epiD sequence (31) . The results of the Edman degradation did not reveal any heterogeneity.
Purified EpiD was yellow. The absorption spectrum exhibited maxima at 274, 382, and 453 nm; these maxima are characteristic for flavoproteins in the oxidized state (36) (Fig. 6A) (33) with the chemical structure of the mature form (1), there is only one obvious reaction that requires an oxidoreductase activity: the removal of two reducing equivalents from a -C-C-group to form a -C=C-group. Such a desaturating reaction takes place at the last cysteine residue of the epidermin C terminus. The postulated modification reaction catalyzed by EpiD is illustrated in Fig. 7 . The C termini of the lantibiotics epidermin, gallidermin (18) , and mersacidin (11) are distinguished by a ring structure in which S-(2-aminovinyl)-D-cysteine represents a characteristic building block. The biochemical synthesis of S-[(Z)-2-aminovinyl]-D-cysteine may proceed in four steps as follows: (i) serine in position + 19 of the primary translational product is dehydrated, forming didehydroala-nine (the removal of water is accompanied by double-bond formation); (ii) the thiol group of the C-terminal cysteine, Cys-22, is linked to the double bond of the didehydroalanine at position 19 , forming the C-terminal meso-lanthionine; (iii) two reducing equivalents are removed from the cysteine residue of the C-terminal meso-lanthionine, forming a -C=C-double bond (this reaction is very likely catalyzed by EpiD); (iv) removal of the C-terminal carboxyl group by a decarboxylase reaction catalyzed by a separate enzyme or occurring spontaneously.
With respect to the order of the modification reactions, we assume that the four lanthionine rings are formed first and then the C-terminal lanthionine is oxidized by EpiD. In the course of the oxNdation, EpiD-FMN becomes reduced. How the enzyme becomes reoxidized is unknown. According to this hypothesis, EpiD very likely catalyzes the final step in the modification of pre-epidermin and its reaction product is then processed by the leader peptidase, forming mature epidermin.
The epiD mutant S. epidermidis Tu3298/EMS11 is unable to synthesize active epidermin. When epiD*, cloned and expressed by using the malE fusion system in E. coli, was sequenced, only a point mutation causing a substitution of Gly-93 by Asp was found, leading to the inability of MBPEpiD* to bind FMN. We conclude that EpiD* is also unable to bind FMN; this is a convincing explanation for the inability of S. epidermidis Tu3298/EMS11 to produce epidermin.
There are two molecular explanations for the inability of MBP-EpiD* to bind FMN: (i) the sequence -Lys-IleAla-Asn-Giy-93-Ile-Cys-Asp-is part of the FMN binding site or (ii) Gl93 is outside the FMN binding site, but its substitution by Asp causes a conformational change in the protein because the additional negative charge leads to detrimental effects on FMN binding. For example, the mutation may prevent disulfide bridging of the nearby cysteine residue and, as a consequence, may lead to a conformational change. Evidence for a profound effect of the mutation on the tertiary structure is the increased insolubility of MBP-EpiD* as compared with that of MBP-EpiD.
We are presently attempting to purify the epidermin precursor from the mutant S. epidennidis Tu3298/EMS11 to use as a substrate for EpiD in the analysis of our model of EpiD function in epidermin biosynthesis. This proposed reaction of EpiD is a completely new posttranslational modification reaction.
